Co-Authors
This is a "connection" page, showing publications co-authored by DEBORAH A KUBAN and STEVEN JAY FRANK.
Connection Strength
4.623
-
Quantification of prostate and seminal vesicle interfraction variation during IMRT. Int J Radiat Oncol Biol Phys. 2008 Jul 01; 71(3):813-20.
Score: 0.324
-
An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol. 2007 Jun; 177(6):2151-6; discussion 2156.
Score: 0.310
-
Improving efficiency and reducing costs of MRI-Guided prostate brachytherapy using Time-Driven Activity-Based costing. Brachytherapy. 2022 Jan-Feb; 21(1):49-54.
Score: 0.207
-
Predictors of urinary toxicity with MRI-assisted radiosurgery for low-dose-rate prostate brachytherapy. Brachytherapy. 2020 Sep - Oct; 19(5):574-583.
Score: 0.193
-
Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer. 2020 02 01; 126(3):506-514.
Score: 0.184
-
Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer. J Clin Oncol. 2018 10 10; 36(29):2943-2949.
Score: 0.169
-
Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial. Am J Clin Oncol. 2018 Jun; 41(6):558-567.
Score: 0.166
-
Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int. 2018 04; 121(4):540-548.
Score: 0.159
-
Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. Int J Radiat Oncol Biol Phys. 2018 02 01; 100(2):374-382.
Score: 0.159
-
The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer. Am J Clin Oncol. 2016 08; 39(4):368-73.
Score: 0.146
-
Assessing the Quality of a Radiation Oncology Case-Based, Peer-Review Program in an Integrated Academic and Community Cancer Center Network. J Oncol Pract. 2016 Apr; 12(4):e476-86.
Score: 0.142
-
Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing. Brachytherapy. 2016 May-Jun; 15(3):274-282.
Score: 0.142
-
Establishing high-quality prostate brachytherapy using a phantom simulator training program. Int J Radiat Oncol Biol Phys. 2014 Nov 01; 90(3):579-86.
Score: 0.128
-
Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1074-84.
Score: 0.125
-
Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients. Prostate Cancer Prostatic Dis. 2013 Dec; 16(4):346-51.
Score: 0.119
-
Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer. 2013 Sep 15; 119(18):3265-71.
Score: 0.118
-
PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. Int J Radiat Oncol Biol Phys. 2013 Jan 01; 85(1):e39-46.
Score: 0.113
-
Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys. 2013 Mar 01; 85(3):693-9.
Score: 0.111
-
Knife or needles? A cohort analysis of outcomes after radical prostatectomy or brachytherapy for men with low- or intermediate-risk adenocarcinoma of the prostate. Brachytherapy. 2012 Nov-Dec; 11(6):429-34.
Score: 0.110
-
Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease? Eur J Cancer. 2012 Jul; 48(11):1664-71.
Score: 0.107
-
Screening colonoscopy before prostate cancer treatment can detect colorectal cancers in asymptomatic patients and reduce the rate of complications after brachytherapy. Pract Radiat Oncol. 2012 Jul-Sep; 2(3):e7-e13.
Score: 0.107
-
Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J. 2012 Jan-Feb; 18(1):1-8.
Score: 0.107
-
Long-term tumor control after brachytherapy for base-of-prostate cancer. J Contemp Brachytherapy. 2011 Dec; 3(4):183-7.
Score: 0.107
-
Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011 Apr 01; 79(5):1310-7.
Score: 0.095
-
A volumetric trend analysis of the prostate and seminal vesicles during a course of intensity-modulated radiation therapy. Am J Clin Oncol. 2010 Apr; 33(2):173-5.
Score: 0.094
-
Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experience. Urology. 2009 Sep; 74(3):601-5.
Score: 0.090
-
Prostogram predicted brachytherapy outcomes are not universally accurate: an analysis based on the M. D. Anderson Cancer Center experience with (125)iodine brachytherapy. J Urol. 2009 Apr; 181(4):1658-63; discussion 1663-4.
Score: 0.087
-
Is a loose-seed nomogram still valid for prostate brachytherapy in a stranded-seed era? Int J Radiat Oncol Biol Phys. 2008 Oct 01; 72(2):623-7.
Score: 0.082
-
Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007 Mar 15; 67(4):1059-65.
Score: 0.076
-
Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. Brachytherapy. 2007 Jan-Mar; 6(1):2-8.
Score: 0.075
-
Increased Frequency of Mesorectal and Perirectal LN Involvement in T4 Prostate Cancers. Int J Radiat Oncol Biol Phys. 2020 08 01; 107(5):982-985.
Score: 0.047
-
Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data. Pract Radiat Oncol. 2020 Jul - Aug; 10(4):282-292.
Score: 0.047
-
Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer. JAMA Netw Open. 2020 03 02; 3(3):e201255.
Score: 0.047
-
Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2019 07 15; 104(4):790-797.
Score: 0.044
-
Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):249-258.
Score: 0.039
-
Proton Beam Therapy for Localized Prostate Cancer: Results from a Prospective Quality-of-Life Trial. Int J Part Ther. 2016; 3(1):27-36.
Score: 0.037
-
Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76.
Score: 0.034
-
Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 Mar; 117(3):469-77.
Score: 0.034
-
Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Dec 01; 87(5):946-53.
Score: 0.030
-
Declining use of brachytherapy for the treatment of prostate cancer. Brachytherapy. 2014 Mar-Apr; 13(2):157-62.
Score: 0.030
-
Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy. Brachytherapy. 2013 May-Jun; 12(3):204-9.
Score: 0.027
-
Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol. 2012 Sep; 23(9):2346-2352.
Score: 0.027
-
Dosimetric impact of fiducial markers in patients undergoing photon beam radiation therapy. Phys Med. 2012 Jul; 28(3):240-4.
Score: 0.026